NVIDIA and Eli Lilly Launch $1 Billion AI Lab to Transform Drug Discovery

Nvidia and Eli Lilly said they will invest up to $1 billion over five years to build a co-innovation lab in the San Francisco Bay Area that applies advanced AI to drug discovery and manufacturing. The venture will run on Nvidia’s BioNeMo platform and its next-generation Vera Rubin architecture, linking Lilly’s automated wet labs with computational “dry” labs in a continuous learning loop aimed at 24/7 experimentation and model refinement. The partners plan to develop large foundation and frontier models for biology and chemistry, and to extend AI into clinical development, medical imaging and plant operations, including digital twins via Nvidia’s Omniverse and RTX PRO servers. The initiative builds on Lilly’s recently announced AI “factory” and underscores Nvidia’s push to deepen its footprint in life sciences. Both companies cautioned that results will depend on execution and regulatory factors. Work is slated to begin early this year.

Read more